Topic overview

Start with the big picture

The lesson organizes schizophrenia around its clinical features, proposed neurotransmitter dysregulation, and pharmacologic management. It introduces second-generation antipsychotics as first-line therapy and compares them with first-generation agents, including differences in adverse-effect concerns. Special attention is given to clozapine in treatment-resistant illness or suicidality, antipsychotic safety warnings, extrapyramidal symptoms, metabolic effects, and neuroleptic malignant syndrome. The topic also covers long-acting injectable formulations and considerations relevant to acute agitation, dosing principles, CYP interactions, and QT prolongation. Together, these areas provide a framework for understanding treatment choices and monitoring priorities without reducing care to medication selection alone.